Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Brian Godman, Holly McCabe, Trudy D Leong, Debjani Mueller, Antony P. Martin, Iris Hoxha, Julius C. Mwita, Godfrey Mutashambara Rwegerera, Amos Massele, Juliana de Oliveira Costa, Renata Cristina Rezende Macedo do Nascimento, Livia Lovato Pires de Lemos, Konstantin Tachkov, Petya Milushewa, Okwen Patrick, Loveline Lum Niba, Ott Laius, Israel Sefah, Suhaj Abdulsalim, Fatemeh Soleymani, Anastasia N Guantai, Loice Achieng, Margaret Oluka, Arianit Jakupi, Konstantīns Logviss, Mohamed Azmi Hassali, Dan Kibuule, Francis Kalemeera, Mwangana Mubita, Joseph Fadare, Olayinka O. Ogunleye, Zikria Saleem, Shazhad Hussain, Tomasz Bochenek, Ileana Mardare, Alian A. Alrasheedy, Jurij Furst, Dominik Tomek, Vanda Markovic-Pekovic, Enos M. Rampamba, Abubakr Alfadl, Adefolarin A Amu, Zinhle Matsebula, Thuy Nguyen Thi Phuong, Binh Nguyen Thanh, Aubrey Chichonyi Kalungia, Trust Zaranyika, Nyasha Masuka, Ioana D. Olaru, Janney Wale, Ruaraidh Hill, Amanj Kurdi, Angela Timoney, Stephen Campbell & Johanna C. Meyer. (2020) Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics & Outcomes Research 20:1, pages 1-26.
Read now
Read now
Juan Pablo Frias. (2019) Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes. Expert Review of Endocrinology & Metabolism 14:2, pages 75-83.
Read now
Read now
André J. Scheen. (2018) The safety of empagliflozin plus metformin for the treatment of type 2 diabetes. Expert Opinion on Drug Safety 17:8, pages 837-848.
Read now
Read now
André J. Scheen. (2017) Pharmacotherapy of ‘treatment resistant’ type 2 diabetes. Expert Opinion on Pharmacotherapy 18:5, pages 503-515.
Read now
Read now
Articles from other publishers (12)
E. V. Biryukova & D. V. Kileynikov. (2023) Metformin and sitagliptin fixed combination as the optimal choice in solving current problems in the type 2 diabetes mellitus treatment. Meditsinskiy sovet = Medical Council 17:9, pages 23-30.
Crossref
Crossref
Amit Kaushal, Sandeep Arora, Neelam Sharma & Sukhbir Singh. (2021) Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach. Current Drug Therapy 16:2, pages 184-203.
Crossref
Crossref
Chia‐Pin Lin, Ying‐Chang Tung, Fu‐Chih Hsiao, Chia‐Hung Yang, Yi‐Wei Kao, Yu‐Sheng Lin, You‐Chia Chu & Pao‐Hsien Chu. (2020) Fixed‐dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. The Journal of Clinical Hypertension 22:10, pages 1846-1853.
Crossref
Crossref
Daryl J. Fediuk, Gianluca Nucci, Vikas Kumar Dawra, David L. Cutler, Neeta B. Amin, Steven G. Terra, Rebecca A. Boyd, Rajesh Krishna & Vaishali Sahasrabudhe. (2020) Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor. Clinical Pharmacokinetics 59:8, pages 949-965.
Crossref
Crossref
Jyoti Singh, Prasad Rasane, Sawinder Kaur, Vikas Kumar, Kajal Dhawan, Dipendra K. Mahato, Sunita Malhotra, Chayanika Sarma, Damanpreet Kaur & Jayatee Bhattacharya. (2020) Nutritional Interventions and Considerations for the Development of Low Calorie or Sugar Free Foods. Current Diabetes Reviews 16:4, pages 301-312.
Crossref
Crossref
Stewart Harris, Martin J. Abrahamson, Antonio Ceriello, Guillaume Charpentier, Marc Evans, Roger Lehmann, Andreas Liebl, Sultan Linjawi, Richard I. G. Holt, Nóra Hosszúfalusi, Guy Rutten & Tina Vilsbøll. (2020) Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes. Drugs 80:2, pages 147-165.
Crossref
Crossref
Lawrence A. Leiter, Alice Y.Y. Cheng, Jean-Marie Ekoé, Ronald M. Goldenberg, Stewart B. Harris, Irene M. Hramiak, Kamlesh Khunti, Peter J. Lin, Jean-François Richard, Peter A. Senior, Jean-François Yale, Lianne Goldin, Mary K. Tan & Anatoly Langer. (2019) Glycated Hemoglobin Level Goal Achievement in Adults With Type 2 Diabetes in Canada: Still Room for Improvement. Canadian Journal of Diabetes 43:6, pages 384-391.
Crossref
Crossref
Tamara Y. Milder, Sophie L. Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R. Greenfield & Richard O. Day. (2019) Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 8:1, pages 45.
Crossref
Crossref
Xiaoling Cai, Xueying Gao, Wenjia Yang, Xueyao Han & Linong Ji. (2018) Efficacy and Safety of Initial Combination Therapy in Treatment-Naïve Type 2 Diabetes Patients: A Systematic Review and Meta-analysis. Diabetes Therapy 9:5, pages 1995-2014.
Crossref
Crossref
Kurt Ritter. 2003. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry
1
37
.
Eugenio Cersosimo, Eric L. Johnson, Christina Chovanes & Neil Skolnik. (2018) Initiating therapy in patients newly diagnosed with type 2 diabetes: Combination therapy vs a stepwise approach. Diabetes, Obesity and Metabolism 20:3, pages 497-507.
Crossref
Crossref
Sunghwan Suh, Sun Ok Song, Jae Hyeon Kim, Hyungjin Cho, Woo Je Lee & Byung-Wan Lee. (2017) Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study). Journal of Diabetes Research 2017, pages 1-8.
Crossref
Crossref